Xagenic Looks To Launch Point-of-Care Molecular Dx Platform Targeting Infectious Disease
This article was originally published in The Gray Sheet
Executive Summary
The start-up has created the Xagenic X1 platform to run molecular diagnostic tests in a physician's office in about 20 minutes instead of sending samples out to a lab. The company plans to address chlamydia and gonorrhea first, and to establish a presence in the sexually transmitted infections, women's health, and urgent and primary care markets.